AGM Chairman address and CEO presentation
Nov 20th, 2020
Attached is the Chairman’s address together with the CEO’s presentation to the Annual General Meeting (AGM) of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY), to be held at 11am (Melbourne time) today.
Read More
SPL7013 shows potent antiviral activity in RSV expanding use for nasal spray
Nov 19th, 2020
Starpharma today announced it has completed additional testing showing potent antiviral activity of SPL7013 against human respiratory syncytial virus (RSV). RSV is a common and very contagious virus that affects the lungs and airways. RSV is most problematic in the young and the elderly and those with weakened immune systems, or chronic heart and lung disease, including asthma. More than 177,000 adults are hospitalized and 14,000 of them die due to RSV infection in the US annually. RSV is also one of the viruses responsible for the common cold.
Read More
Quarterly Cashflow and Activities Report
Oct 30th, 2020
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 September 2020.
Read More
Completion of Placement and SPP raises $48.9M in total
Oct 29th, 2020
Starpharma today announced that it has completed its Share Purchase Plan (SPP), raising $3.9 million. The SPP was conducted in conjunction with Starpharma’s recent institutional placement (Placement), which together have raised a total of $48.9 million. The issue of 2.6 million new shares under the SPP will be at $1.50 per share, being equivalent to the Placement share price.
Read More
Starpharma receives $5.7M R&D tax incentive refund
Oct 21st, 2020
Starpharma today announced that it has received a $5.7M R&D tax incentive refund which relates to the costs of research and development during the 2020 Financial Year. The refund is in respect of eligible R&D activities across Starpharma’s portfolio, including for COVID-19, DEP® and VivaGel® programs.
Read More
Shareholder Update October 2020
Oct 20th, 2020
In this issue:
>> Starpharma is expediting the development of the SPL7013 COVID‑19 nasal spray
>> Rapid progress in the DEP® irinotecan phase 2 & preparations underway for clinical combinations
>> DEP® irinotecan in combination with immuno-oncology showed superior performance in colon cancer models
>> VivaGel® BV launched in Central & Eastern Europe and Nordic region
>> Fleurstat BVgel gains expanded TGA approval to include prevention of recurrent Bacterial Vaginosis (BV) indication
>> VivaGel® BV has now been approved in 40 countries with further submissions underway
>> Starpharma awarded $1 million MRFF funding for COVID-19 nasal spray
>> DEP® docetaxel update & patient case study
>> DEP® cabazitaxel update & patient case study
>> Multiple DEP® products showcased at AACR 2020 Annual Meeting
>> New DEP® partnership signed with Chase Sun for anti-infective program
>> AstraZeneca’s AZD0466 trial opens at MD Anderson Cancer Center
>> Starpharma creates slow release soluble DEP® remdesivir
>> DEP® partnering, including Antibody Drug Conjugates
>> DEP® lutetium; impressive efficacy in human prostate cancer model
>> Outlook, Annual Report & ESG Report & recent news
Read More
Share Purchase Plan offer document
Oct 7th, 2020
Starpharma provides the offer document for the Company's 2020 Share Purchase Plan (SPP).
Read More
Starpharma completes oversubscribed A$45M placement - SPP to follow
Sep 30th, 2020
Starpharma today announced that it has raised A$45 million via a placement to domestic and international institutional, sophisticated and professional investors (“Placement”). Eligible shareholders will also have the opportunity to participate, at the same price, through a Share Purchase Plan (SPP) which is expected to raise approximately A$5 million.
Read More
Investor Presentation
Sep 30th, 2020
Starpharma today provided its latest investor presentation.
Read More
VivaGel® BV secures TGA approval for prevention of BV
Sep 25th, 2020
Starpharma today announced that the Australia Therapeutic Goods Administration (TGA) has approved an expansion of the marketing authorisation for VivaGel® BV (Fleurstat BVgel) to now include the indication of prevention of recurrent bacterial vaginosis. These expanded claims bring the approved indications for VivaGel® BV (Fleurstat BVgel) in line with those in Europe and Asia.
Read More
Starpharma to present at OTCQX Life Sciences Investor Forum
Sep 17th, 2020
Starpharma today announced that a pre-recorded presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 17 September 2020 (US ET) as part of OTCQX’s Life Sciences Investor Forum.
Read More
SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
Sep 14th, 2020
Starpharma today announced it has completed additional antiviral testing for SPL7013 against SARS‑CoV-2 in studies conducted in the laboratory of internationally recognised virology researcher, Professor Philippe Gallay, at the renowned Scripps Research Institute in the US.
Read More
Starpharma awarded $1M MRFF funding for COVID-19 spray
Sep 3rd, 2020
Starpharma today announced the award of $1 million in matched funding by the Australian Government’s Medical Research Future Fund (MRFF) Biomedical Translation Bridge (BTB) Program to expedite development and commercialisation of its COVID‑19 antiviral nasal spray based on Starpharma’s proprietary dendrimer, SPL7013.
Read More
SPL creates slow release soluble DEP® remdesivir nanoparticle
Sep 1st, 2020
Starpharma today announced it has applied its novel DEP® drug delivery technology to create a long‑acting, water soluble version of remdesivir. Remdesivir is an antiviral drug, currently being developed by Gilead to treat COVID-19 and has emergency use authorisation from the US Food and Drug Administration for the treatment of COVID-19 in adults and children hospitalised with severe disease.
Read More
Annual report and full year financial results
Aug 27th, 2020
Melbourne, Australia: Starpharma today released its annual report and financial results for the year ended 30 June 2020.
Read More
2GB’s Jim Wilson interviews Starpharma CEO Dr Jackie Fairley
Aug 26th, 2020
2GB radios Jim Wilson interviewed Starpharma CEO Dr Jackie Fairley to get an update on how Starpharma is fast-tracking a nasal spray designed to be used as a preventative measure in the fight against COVID-19.
To listen to the full interview click here.
Read More
ABC News features Starpharma on ‘The Kohler Report’
Aug 26th, 2020
Starpharma was featured on ABC’s finance news segment ‘The Kohler Report’, where Alan Kohler highlighted that Starpharma shares had risen 23% following the Company’s update on its SPL7013-based antiviral nasal spray, which has shown to have potent antiviral activity against COVID-19. The update included that Starpharma has commenced confidential commercial discussions with related parties.
To watch the full report, click here.
Read More
Australian Manufacturing writes about Starpharma identifying a manufacturer of its antiviral nasal spray for COVID-19
Aug 26th, 2020
Starpharma was recently featured in an article by Australian Manufacturing, a leading publication and resource for the manufacturing and industrial sector in Australia. The article noted Starpharma had undertaken a pilot manufacture for its SPL7013 antiviral nasal spray, which has been tested and confirmed to have potent antiviral activity against SARS-CoV-2, the virus that causes COVID-19. The article also highlightsed SPL has identified a manufacturer and are currently compiling documentation in preparation for regulatory submission.
To read the full article click here.
Read More
SPL7013 nasal spray for COVID-19 – development update
Aug 25th, 2020
Starpharma today announced progress with development, regulatory and manufacturing activities associated with a nasal spray for protection against COVID-19 based on the company’s proprietary antiviral dendrimer, SPL7013.
Read More
Starpharma signs new DEP® partnership with Chase Sun
Aug 17th, 2020
Starpharma today announced that it has signed a new research partnership with leading Chinese Pharmaceutical company Tianjin Chase Sun Pharmaceutical Co., Ltd. (stock code 300026; Chase Sun), to develop several DEP® nanoparticle formulations for an anti-infective drug. The agreement also provides for the potential to conduct additional DEP® programs, which can be across therapeutic areas beyond anti-infectives.
Read More
Quarterly Cashflow and Activities Report
Jul 30th, 2020
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 June 2020.
Read More
DEP® docetaxel and gemcitabine combination trial commences
Jul 30th, 2020
Starpharma today announced that it has commenced its DEP® docetaxel + gemcitabine combination study for patients with advanced cancers, including pancreatic cancer. Recruitment into the study has commenced at the Christie in the UK, with two further sites expected to open in the coming weeks.
Read More
AZD0466 trial opens MD Anderson Cancer Center as a site
Jul 27th, 2020
Starpharma (ASX: SPL, OTCQX: SPHRY) today announced the opening of the MD Anderson Cancer Center as a further trial site for the phase 1 trial of AZD0466, AstraZeneca’s first DEP® product.
Read More
New Australian site opening for DEP® trials
Jul 9th, 2020
Starpharma today announced the opening of a new trial site for the phase 2 DEP® irinotecan trial, at the Kinghorn Cancer Centre in Sydney. The DEP® irinotecan trial is also being conducted at multiple leading UK cancer centres including The Christie, The Royal Marsden, Newcastle Freeman Hospital, and The Beatson West of Scotland Cancer Centre. The Kinghorn Cancer Centre will also be opened shortly as an additional site for the phase 2 DEP® cabazitaxel trial.
Read More
The Age: Starpharma CEO Dr Jackie Fairley on Australia’s need to turn homegrown research into commercial products
Jul 3rd, 2020
The Age interviewed Starpharma CEO Dr Jackie Fairley about how the COVID-19 pandemic could be the much needed catalyst for the pharmaceutical industry to improve the way they convert important research into commercial products. Dr Fairley also covered Starpharma’s recent activities in response to the pandemic including, the development of a nasal spray product using the antiviral dendrimer, SPL7013.
To read the full interview click here.
Read More
Pandemic a catalyst for boosting commercial outcomes, says Starpharma CEO
Jul 3rd, 2020
The Age recently interviewed Starpharma CEO Dr Jackie Fairley to discuss how the COVID19 pandemic could be the catalyst for the pharmaceutical industry to improve the way they convert important research into commercial products. The article highlighted Starpharma’s recent activities in response to the pandemic, including the development of a product using its existing anti-viral dendrimer SPL7013.
To read the full article, click here.
Read More
DEP irinotecan boosts immuno-oncology in colon cancer models
Jun 29th, 2020
Starpharma today announced its SN-38 nanoparticle, DEP® irinotecan in combination with an immuno-oncology (IO) agent (anti PD-1 antibody) showed superior anti-tumour activity and significant survival benefit in two colorectal cancer (CRC) models when compared to the anti PD-1 antibody alone. These results included improvement in both survival and efficacy in the particularly aggressive CT-26 CRC model.
Read More
The 7.30 report interviews Starpharma CEO Dr Jackie Fairley
Jun 25th, 2020
The ABC’s 7:30 report interviewed Starpharma CEO Dr Jackie Fairley to discuss the importance of creating COVID-19 preventative products while the world waits for a vaccine to be developed. Dr Fairley discussed how Starparma’s patented dendrimer SPL7013 has shown significant anti-viral activity against SARS-CoV-2 (coronavirus) and how quickly a product using this ingredient could be brought to market given its approval and use in other marketed products.
Watch the full interview click here.
Read More
Starpharma CEO Dr Jackie Fairley on the ABC’s 7.30 report
Jun 25th, 2020
Alan Kohler recently interviewed Starpharma CEO Dr Jackie Fairley on the ABC’s 7.30 report to discuss the importance of developing other methods of protection against COVID-19 while we wait for a vaccine. Jackie also discusses how Starpharma’s patented dendrimer SPL7013 is being developed for use in an antiviral nasal spray to prevent COVID-19 infection.
Watch the full interview here: https://www.abc.net.au/7.30/how-long-will-the-economy-take-to-recover/12394342
Read More
Multiple DEP® products showcased at AACR 2020
Jun 23rd, 2020
Starpharma today announced that five posters featuring products based on Starpharma’s DEP® platform have been presented at the AACR (American Association for Cancer Research) Annual Meeting. The AACR Annual Meeting brings together leading cancer research and medicine from institutions all over the world and is an important forum for both raising product awareness and commercial interactions.
Read More
SBS speaks to Starpharma CEO Dr Jackie Fairley on female representation in business
Jun 19th, 2020
A new study using Australian data showed a causal link between female leadership and business performance. Starpharma is one of only 15 ASX300 companies to have a female CEO and Dr Jackie Fairley spoke with SBS about the importance of having senior female leaders in a corporate setting.
For the full interview click here.
Read More
Ausbiz interviews Starpharma CEO Dr Jackie Fairley
Jun 19th, 2020
Finance and market news website AusBiz interviewed Starpharma CEO Dr Jackie Fairley to discuss the company’s first radiotherapeutic candidate, DEP® lutetium. The candidate showed highly statistically significant anticancer activity, tumour regression and 100% survival in a human prostate cancer model. The interview also covered the company’s latest VivaGel® BV launch in Central and Eastern Europe.
To watch the full interview click here.
Read More
Starpharma to present at OTCQX Virtual Investor Conference
Jun 18th, 2020
Starpharma today announced that a pre-recorded presentation by Dr Jackie Fairley, CEO, will be broadcast on Thursday 18 June 2020 (US ET) as part of OTCQX’s Virtual Investor Conference for Global Mid-cap and Large-cap Companies. The conference is primarily attended by US-based retail investors, as well as advisors.
Read More
DEP® lutetium effective in human prostate cancer model
Jun 17th, 2020
Starpharma today announced results from its first radiotherapeutic candidate, DEP® lutetium. DEP® lutetium is a patented nanoparticle which incorporates the radioisotope Lutetium-177 on a DEP® dendrimer scaffold.
Read More
VivaGel® BV launched in central and eastern European countries
Jun 16th, 2020
Starpharma today announced that VivaGel® BV has been launched in Central and Eastern European (CEE) region. This launch follows European launches in Germany, UK and several other European countries.
Read More
Starpharma CEO Dr Jackie Fairley on Proactive Investors (Canada)
May 18th, 2020
The Canadian arm of finance news network Proactive Investors recently interviewed Starpharma CEO Dr Jackie Fairley to discuss the Company's DEP® portfolio and the recent news that Starpharma is investigating product concepts for proprietary dendrimer SPL7013 in relation to COVID-19.
Watch the full interview here: https://www.youtube.com/watch?v=jqn06bUymDw&feature=youtu.be
Read More
Shareholder Update May 2020
May 14th, 2020
In this issue:
>> VivaGel® BV launched in Asia
>> Fleurstat BVgel launched in NZ
>> DEP® irinotecan phase 2 commences after positive phase 1 results
>> SPL7013 against SARS-COV-2 (coronavirus)
>> Fleurstat BVgel ranks as #1 topical BV treatment
>> Okamoto adds 11 more Asian countries to licence
>> US regulatory update
>> COVID-19: Starpharma’s operations continue with minimal disruption
>> DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan
>> DEP® patient case studies
>> AstraZeneca’s DEP® trial ongoing in the US & US$3 million milestone payment received
>> New DEP® ADC programs
>> DEP® pipeline targets multiple high-value areas
>> Other DEP® programs
>> Outlook, recent news & events
Read More
Starpharma CEO Dr Jackie Fairley on ausbiz
May 11th, 2020
Finance and market news website AusBiz co-founders Kylie Merritt and David Koch interviewed Starpharma CEO Dr Jackie Fairley to discuss DEP® irinotecan moving into Phase 2 and how Starpharma is investigating product concepts for SPL7013 in the fight against COVID-19.
To watch the full interview click here
Read More
DEP® irinotecan phase 2 commences after positive phase 1 results
May 7th, 2020
Starpharma today announced successful completion of the phase 1 component of its phase 1 / 2 trial for DEP® irinotecan. The trial met its objective of evaluating safety, tolerability, pharmacokinetics and preliminary efficacy data, and identifying a recommended phase 2 dose. The trial will now transition seamlessly into phase 2, with recruitment activities underway at three sites. Two additional sites, The Beatson West of Scotland Cancer Centre (the Beatson) and the Kinghorn Cancer Centre in Sydney are also expected to commence recruitment shortly.
Read More
Starpharma presents at Macquarie Australia Conference
May 5th, 2020
Starpharma has been invited to present today at the Macquarie Australia Conference. Due to COVID-19, the Macquarie Australia Conference will be a virtual conference for registered institutional investors. The event will provide international and domestic institutions with the opportunity to hear from a range of invited Australian companies over three days. Starpharma is one of a handful of companies in the pharmaceutical/biotech and healthcare industries to be presenting during the conference.
Read More
Australia’s biotech sector tests multiple agents to fight COVID-19
Apr 22nd, 2020
US biotech publication BioWorld noted that a number of Australian biotech companies have been testing agents in the fight against COVID-19, in particular highlighting Starpharma’s SPL7013 which showed significant positive antiviral activity against the SARS-CoV-2 virus.
To read the full article, click here
Read More
Condom gel compound proves effective against COVID-19
Apr 16th, 2020
The Australian Financial Review interviewed Starpharma CEO Dr Jackie Fairley for an article highlighting the company’s finding that its antiviral dendrimer SPL7013 showed significant activity against coronavirus. The article noted SPL7013 is already used in existing and approved products within Starpharma’s VivaGel® portfolio.
To read the full article, click here (paywall).
Read More
Starpharma Reports Positive Results From SARS-CoV-2 Antiviral Testing Of SPL7013
Apr 16th, 2020
NASDAQ covered the news that Starpharma’s VivaGel® active, astodrimer sodium (SPL7013), showed significant antiviral activity against the coronavirus that causes COVID-19. The piece noted the testing was conducted by an external laboratory, 360Biolabs.
To read the full article, click here.
Read More
Starpharma’s SPL7013 Shows Significant Activity Against SARS-CoV-2 (coronavirus)
Apr 16th, 2020
Leading biotech industry portal BioSpace covered Starpharma’s finding that its proprietary dendrimer SPL7013 showed significant activity against SARS-CoV-2, the coronavirus that causes COVID-19. It noted Starpharma will evaluate product concepts and formulation options for SPL7013 which may have potential applications in the prevention and management of COVID-19.
To read the full article, click here
Read More
SPL7013 shows significant activity against SARS-CoV-2 (coronavirus)
Apr 15th, 2020
Starpharma today announced that its proprietary VivaGel® active, astodrimer sodium (SPL7013), has been shown in laboratory studies to have significant antiviral activity against the coronavirus that causes COVID-19 (coronavirus disease). SPL7013 inhibited the infection of cells with the SARS-CoV-2 virus and the finding was validated by replicate testing against a positive control compound, remdesivir (Gilead), which is considered a leading candidate for the treatment of COVID-19. The finding was also significant given that SPL7013 was reported to be the best performing test compound against SARS-CoV-2 in the laboratory’s assay to date. With these positive results, Starpharma is evaluating product concepts and formulation options for SPL7013, which may have potential applications in the prevention and management of COVID-19.
Read More
Quarterly Cashflow and Activity Report
Apr 7th, 2020
Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2020.
Starpharma’s cash balance as at 31 March 2020 was $36.1 million, an increase of $0.2 million compared to the previous quarter’s cash balance. Net operating cash outflows for the quarter were $0.9 million, or $6.0 million for the nine months to 31 March 2020. Starpharma’s strong cash reserves and clean balance sheet places the Company in a strong position to continue to progress its commercial and R&D activities in the current uncertain global environment of the COVID-19 pandemic.
Read More
COVID-19 measures
Mar 30th, 2020
Starpharma continues to closely monitor the COVID-19 pandemic and its impact.
Okamoto licenses VivaGel® antiviral condom in Asian countries
Mar 4th, 2020
Starpharma today announced that following the successful launch of the VivaGel® antiviral condom by Okamoto Industries, Inc. (TYO: 5122:JP; Okamoto) in Japan, Okamoto has sought an expansion to its licence territory for the VivaGel® condom. As a result, Starpharma has granted Okamoto marketing rights to a further 11 countries in Asia which include South Korea, Indonesia, Malaysia, Thailand, Singapore and the non-government China market.
Read More
Starpharma appoints David McIntyre and Appendix 3X
Mar 2nd, 2020
Starpharma today announced that Mr David McIntyre has commenced as an independent non-executive director of Starpharma, effective 1 March. Mr McIntyre’s appointment follows a comprehensive Board renewal and search process. As advised at the Company’s last AGM, Mr Richard Hazleton will be retiring at the 2020 AGM in November, having served 13 years on the Company’s Board. The timing of Mr McIntyre’s appointment enables a smooth transition and handover between directors.
Read More
Interim Report and Half-Year Financial Results
Feb 24th, 2020
Starpharma today released its interim report and financial results for the half-year ended 31 December 2019.
Read More